FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC

Oncotarget

Volumn 6, Issue 14, 2015, Pages 12697-12709

  Morra, Francesco ^a,b   Luise, Chiara ^a   Merolla, Francesco ^a,b   Poser, Ina ^c   Visconti, Roberta ^a   Ilardi, Gennaro ^b   Paladino, Simona ^b   Inuzuka, Hiroyuki ^d   Guggino, Gianluca ^e   Monaco, Roberto ^e   Colecchia, David ^f   Monaco, Guglielmo ^e   Cerrato, Aniello ^a   Chiariello, Mario ^f   Denning, Krista ^g   Claudio, Pier Paolo ^h   Staibano, Stefania ^b   Celetti, Angela ^a  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS   (Germany)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e CARDARELLI HOSPITAL   (Italy)

^f ISTITUTO TOSCANO TUMORI   (Italy)

^g Joan C Edwards School of Medicine   (United States)

^h MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CCDC6; Cisplatinum; FBXW7; Mitotic kinases; USP7

Indexed keywords

DEUBIQUITINASE; MEMBRANE PROTEIN; PROTEIN CCDC6; PROTEIN FBXW7; UBIQUITIN SPECIFIC PROTEASE 7; UNCLASSIFIED DRUG; CCDC6 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYTOSKELETON PROTEIN; F BOX PROTEIN; FBXW7 PROTEIN, HUMAN; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE; UBIQUITIN THIOLESTERASE; USP7 PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; CANCER PROGNOSIS; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NON SMALL CELL LUNG CANCER; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; REGULATORY MECHANISM; UBIQUITINATION; ADULT; AGED; CELL CYCLE; DRUG RESISTANCE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE INACTIVATION; GENETIC TRANSFECTION; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR CELL LINE; VERY ELDERLY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYTOSKELETAL PROTEINS; DRUG RESISTANCE, NEOPLASM; F-BOX PROTEINS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCKOUT TECHNIQUES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TRANSFECTION; UBIQUITIN THIOLESTERASE; UBIQUITIN-PROTEIN LIGASES;

EID: 84930030148     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3708     Document Type: Article

References (49)

1. Bartek J, Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol. 2007; 19: 238-45.
2. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell. 2007; 28: 739-45.
3. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004; 432: 316-23.
4. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 2003; 3: 155-68.
5. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000; 408: 433-9.
6. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001; 411366-74.
7. Celetti A, Cerrato A, Merolla F, Vitagliano D, Vecchio G, Grieco M. H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization. Oncogene. 2004; 23: 109-21.
8. Merolla F, Pentimalli F, Pacelli R, Vecchio G, Fusco A, Grieco M, Celetti A. Involvement of H4(D10S170) protein in ATM-dependent response to DNA damage. Oncogene. 2007; 26: 6167-75.
9. Merolla F, Luise C, Muller MT, Pacelli R, Fusco A, Celetti A. Loss of CCDC6, the first identified RET partner gene, affects pH2AX S139 levels and accelerates mitotic entry upon DNA damage. PLoS One. 2012; 7:e36177.
10. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990; 60: 557-63.
11. Drechsler M, Hildebrandt B, Kündgen A, Germing U, Royer-Pokora B. Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and longterm responsiveness to imatinib. Ann Hematol. 2007; 86: 353-4.
12. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012; 18: 378-81.
13. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012; 150: 1107-20.
14. Morra F, Luise C, Visconti R, Staibano S, Merolla F, Ilardi G, Guggino G, Paladino S, Sarnataro D, Franco R, Monaco R, Zitomarino F, Pacelli R, et al. New therapeutic perspectives in CCDC6 deficient lung cancer cells. Int J Cancer. 2015; 136: 2146-57.
15. Zhao J, Tang J, Men W, Ren K. FBXW7-mediated degradation of CCDC6 is impaired by ATM during DNA damage response in lung cancer cells. FEBS Lett. 2012; 586: 4257-63.
16. Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer. 2006; 6: 776-88.
17. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R. A genomic and functional inventory of deubiquitinating enzymes. Cell. 2005; 123: 773-86.
18. Nijman SM, Huang TT, Dirac AM, Brummelkamp TR, Kerkhoven RM, D'Andrea AD, Bernards R. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell. 2005; 17: 331-9.
19. Zhang D, Zaugg K, Mak TW, Elledge SJ. A role for the deubiquitinating enzyme USP28 in control of the DNAdamage response. Cell. 2006; 126: 529-42.
20. Li M, Brooks CL, Kon N, Gu W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell. 2004; 13: 879-86.
21. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell. 2009; 138: 389-403.
22. Brito DA, Rieder CL. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol. 2006; 16: 1194-200.
23. Poser I, Sarov M, Hutchins JR, Hériché JK, Toyoda Y, Pozniakovsky A, Weigl D, Nitzsche A, Hegemann B, Bird AW, Pelletier L, Kittler R, Hua S, et al. BAC TransgeneOmics: a high-throughput method for exploration of protein function in mammals. Nat Methods. 2008; 5: 409-15.
24. Davis FM, Tsao TY, Fowler SK, Rao PN. Monoclonal antibodies to mitotic cells. Proc Natl Acad Sci USA. 1983; 80: 2926-30.
25. Westendorf JM, Rao PN, Gerace L. Cloning of cDNAs for M-phase phosphoproteins recognized by the MPM2 monoclonal antibody and determination of the phosphorylated epitope. Proc Natl Acad Sci USA. 1994; 91: 714-8.
26. Yaffe MB, Schutkowski M, Shen M, Zhou XZ, Stukenberg PT, Rahfeld JU, Xu J, Kuang J, Kirschner MW, Fischer G, Cantley LC, Lu KP. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science. 1997; 278: 1957-60.
27. Wang Z, Inuzuka H, Zhong J, Wan L, Fukushima H, Sarkar FH, Wei W. Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett. 2012; 586: 1409-18.
28. Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, Vogelstein B, Lengauer C. Inactivation of hCDC4 can cause chromosomal instability. Nature. 2004; 428: 77-81.
29. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature. 2001; 413: 316-22.
30. Leone V, Mansueto G, Pierantoni GM, Tornincasa M, Merolla F, Cerrato A, Santoro M, Grieco M, Scaloni A, Celetti A, Fusco A. CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1. Oncogene. 2010; 29: 4341-51.
31. Luise C, Merolla F, Leone V, Paladino S, Sarnataro D, Fusco A, Celetti A. Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity. PLoS One. 2012; 7:e49298.
32. Cummins JM, Rago C, Kohli M, Kinzler KW, Lengauer C, Vogelstein B. Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature. 2004; 428: 1-2.
33. Nicholson B, Suresh Kumar KG. The multifaceted roles of USP7: new therapeutic opportunities. Cell Biochem Biophys. 2011; 60: 61-8.
34. Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP, Weinstock J, Kingsbury WD, Hideshima T, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012; 22: 345-58.
35. Wang Z, Liu P, Inuzuka H, Wei W. Roles of F-box proteins in cancer. Nat Rev Cancer. 2014; 14: 233-47.
36. Onoyama I, Nakayama KI. Fbxw7 in cell cycle exit and stem cell maintenance: insight from gene-targeted mice. Cell Cycle. 2008; 7: 3307-13.
37. Malyukova A, Dohda T, von der Lehr N, Akhoondi S, Corcoran M, Heyman M, Spruck C, Grandér D, Lendahl U, Sangfelt O. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res. 2007; 67: 5611-6.
38. Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, Mueller-Holzner E, Corcoran M, Dagnell M, et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 2007; 67: 9006-12.
39. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2008; 8(2): 83-93.
40. Minella AC, Clurman BE. Mechanisms of tumor suppression by the SCF(Fbw7). Cell Cycle. 2005; 4: 1356-9.
41. Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S, Balmain A. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature. 2004; 432: 775-9.
42. Spruck CH, Strohmaier H, Sangfelt O, Müller HM, Hubalek M, Müller-Holzner E, Marth C, Widschwendter M, Reed SI. hCDC4 gene mutations in endometrial cancer. Cancer Res. 2002; 62: 4535-9.
43. Knuutila S, Aalto Y, Autio K, Björkqvist AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML, Lushnikova T, Monni O, Pere H, et al. DNA copy number losses in human neoplasms. Am J Pathol. 1999; 155: 683-94.
44. Masuya D, Huang C, Liu D, Nakashima T, Yokomise H, Ueno M, Nakashima N, Sumitomo S. The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways. J Pathol. 2006; 208: 724-32.
45. Matsubara D, Kanai Y, Ishikawa S, Ohara S, Yoshimoto T, Sakatani T, Oguni S, Tamura T, Kataoka H, Endo S, Murakami Y, Aburatani H, Fukayama M, Niki T. Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad. J Thorac Oncol. 2012; 7: 1872-6.
46. Chou TC, Talaly P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem. 1977; 252: 6438-42.
47. Staibano S, Ilardi G, Leone V, Luise C, Merolla F, Esposito F, Morra F, Siano M, Franco R, Fusco A, Chieffi P, Celetti A. Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors. BMC Cancer. 2013; 13: 433-40.
48. Paladino S, Pocard T, Catino MA, Zurzolo C. GPI-anchored proteins are directly targeted to the apical surface in fully polarized MDCK cells. J Cell Biol. 2006; 172: 1023-34.
49. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17: 1471-4.